Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1808720 | 0.98 | LMNA (0.58) | LMNATHRBHTTTP53MME | |
| SCHEMBL5780210 | 0.86 | LMNA (0.58) | LMNATHRBHTTTP53MME | |
| SCHEMBL21883784 | 0.82 | LMNA (0.46) | LMNATHRBTP53MMEMAPT | |
| SCHEMBL3823428 | 0.82 | LMNA (0.61) | LMNATHRBTP53MMEMAPT | |
| SCHEMBL1808799 | 0.80 | TP53 (0.66) | LMNATHRBTP53MAPTALDH1A1 | |
| SCHEMBL10924892 | 0.78 | LMNA (0.51) | LMNATHRBTP53MAPTHDAC3 | |
| SCHEMBL10928806 | 0.78 | THRB (0.56) | LMNATHRBTP53MAPTHDAC3 | |
| SCHEMBL8132190 | 0.78 | TP53 (0.52) | LMNATHRBHTTTP53MME | |
| SCHEMBL2254217 | 0.78 | ADRA1D (0.50) | LMNATHRBHTTTP53MAPT | |
| SCHEMBL8149851 | 0.76 | TP53 (0.53) | LMNATHRBTP53MAPTHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727551-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-09-09 | — | — | EP | claimed |
| CN-100496499-C | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein | ARROW THERAPEUTICS LTD (GB) | 2009-06-10 | — | — | CN | claimed |
| US-20080139536-A1 | Benzodiazepines for Treating or Preventing Rsv Infection | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2008-06-12 | — | — | US | claimed |
| US-20070293482-A1 | Process for Preparing Benzodiazepines | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-12-20 | — | — | US | claimed |
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-08-09 | — | — | US | claimed |
| CN-1933841-A | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | ARROW THERAPEUTICS LTD (GB) | 2007-03-21 | — | — | CN | claimed |
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| EP-3369732-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-10787482-B2 | Epoxyketone compounds for enzyme inhibition | Centrax International Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-10711013-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2020-07-14 | — | — | US | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| CN-1933841-A | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | ARROW THERAPEUTICS LTD (GB) | 2007-03-21 | — | — | CN | disclosed |
| EP-1740185-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING RSV INFECTION | Arrow Therapeutics Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| EP-1727551-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005089770-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING OR PREVENTING RSV INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005089771-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | GABRP, TSPO, GABRA1 | LMNA 1760/4885THRB 3183/4885HTT 3035/4885 |
| US-10787482-B2 | Epoxyketone compounds for enzyme inhibition | PSMD10, PSMC1, PSMB10 | LMNA 2177/4885THRB 4088/4885HTT 2813/4885 |
| US-20070293482-A1 | Process for Preparing Benzodiazepines | CNR1, SIGMAR1, GABRA3 | LMNA 1532/4885THRB 414/4885HTT 1933/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | LMNA 2587/4885THRB 3096/4885HTT 1788/4885 |
| US-10711013-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | LMNA 4479/4885THRB 262/4885HTT 4286/4885 |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | LMNA 4479/4885THRB 262/4885HTT 4286/4885 |
| US-11046713-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | LMNA 4479/4885THRB 262/4885HTT 4286/4885 |
| US-20080139536-A1 | Benzodiazepines for Treating or Preventing Rsv Infection | CNR1, CBR1, CBR3 | LMNA 1867/4885THRB 471/4885HTT 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.